Oncology, Diabetes Dominate Korean Out-Licensing But Deals And Value Decline

Scrip takes a look at how the South Korean pharma/biotech industry's cross-border deals over the past few years compare with global trends, finding that oncology and diabetes have been the dominant therapeutic areas for the out-licensing of assets, but recent activity and value have declined from a peak in 2015.

Handshake
HOW DO KOREAN DEAL TRENDS COMPARE WITH GLOBAL NORMS? • Source: Shutterstock

Oncology and diabetes dominated cross-border out-licensing deals by South Korean pharma/biotech companies over the 2015 to 2017 period, largely in line with the trends in global pharma, but the total number and value of deals in the Asian country declined over the period despite the domestic industry's ongoing efforts to seek overseas partners and enter international markets.

The number of cross-border out-licensing deals by Korean companies fell to nine in 2017 from 14 in 2015, largely affected...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from South Korea

More from Focus On Asia